Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human ADCY5 Anticorps:
anti-Mouse (Murine) ADCY5 Anticorps:
anti-Rat (Rattus) ADCY5 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Mouse (Murine) Polyclonal ADCY5 Primary Antibody pour CM, ICC - ABIN2746164
Kolachala, Asamoah, Wang, Srinivasan, Merlin, Sitaraman: Interferon-gamma down-regulates adenosine 2b receptor-mediated signaling and short circuit current in the intestinal epithelia by inhibiting the expression of adenylate cyclase. dans The Journal of biological chemistry 2005
Show all 3 Pubmed References
Human Polyclonal ADCY5 Primary Antibody pour WB - ABIN2801949
Wicker, Catalan, Cailleux, Starenki, Stengel, Sarasin, Suarez: Cloning and expression of human adenylyl cyclase type VI in normal thyroid tissues. dans Biochimica et biophysica acta 2000
Show all 5 Pubmed References
Human Monoclonal ADCY5 Primary Antibody pour ELISA, WB - ABIN513118
Drescher, Cho, Folbe, Selvakumar, Kewson, Abu-Hamdan, Oh, Ramakrishnan, Hatfield, Khan, Anne, Harpool, Drescher: An adenylyl cyclase signaling pathway predicts direct dopaminergic input to vestibular hair cells. dans Neuroscience 2010
Human Polyclonal ADCY5 Primary Antibody pour ICC, IF - ABIN408294
Oh, Hwang, Lee, Choi, Kim, Kim, Sadovsky, Roh: Isolation of basal membrane proteins from BeWo cells and their expression in placentas from fetal growth-restricted pregnancies. dans Placenta 2016
Mutations in ADCY5 are responsible for a hyperkinetic movement disorder that can be preceded by episodic attacks before the movement disorder becomes persistent and is frequently misdiagnosed as dyskinetic cerebral palsy.
In this series of five ADCY5 mutation carriers, perioral twitches and truncal jerks do not represent myokymia
ADCY5-related dyskinesia may manifest variable expressivity within a single family, and affected individuals may be initially diagnosed with differing neurological phenotypes.
ADCY5 gene mutations can present with a wider variety of movement disorder syndromes.
ADCY5, which encodes adenylyl cyclase type 5, and RAP2C (Montrer RAP2C Anticorps), which encodes a member of the RAS oncogene (Montrer RAB1A Anticorps) family, had associations of nearly genomewide significance. ADCY5 locus have been reported to be associated with birth weight and type 2 diabetes however, none were in linkage disequilibrium with the SNPs showing significant association with gestational duration.
These data suggest that rs11708067-A risk allele contributes to type 2 diabetes by disrupting an islet enhancer, which results in reduced ADCY5 expression and impaired insulin (Montrer INS Anticorps) secretion.
This study demonstrated that whole-exome sequencing show reveled ADCY5 mutation with early-onset generalized dystonia.
the clinical spectrum of ADCY5 mutations encompasses paroxysmal weakness in addition to paroxysmal dyskinesia and persistent hyperkinesia, nominating ADCY5 mutations as a genetic cause of unexplained alternating hemiplegia of childhood.
This study showed that ADCY5 mutation carriers display pleiotropic paroxysmal day and nighttime dyskinesias.(
Risk alleles for 6 loci increased glucose levels from birth to 5 years of age (ADCY5, ADRA2A (Montrer ADRA2A Anticorps), CDKAL1 (Montrer CDKAL1 Anticorps), CDKN2A/B, GRB10 (Montrer GRB10 Anticorps), and TCF7L2 (Montrer TCF7L2 Anticorps)
AC5 mutation produces autistic-like symptoms through the upregulation of mGluR5 (Montrer GRM5 Anticorps) functions in the dorsal striatum and that the dorsal striatum regulated by AC5 is a neural correlate responsible for core Autism spectrum disorders symptoms
Results show that both ATP and Gsalpha binding have significant effects on the structure and flexibility of adenylyl cyclase. New data on ATP bound to AC5 in the absence of Gsalpha notably help to explain how Gsalpha binding enhances enzyme activity and could aid product release. Simulations also suggest a possible coupling between ATP binding and interactions with the inhibitory G-protein subunit Galphai.
AC5 knockout mice, without exercise training, share similar mechanisms responsible for enhanced exercise capacity with chronic exercise training.
Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in a model of autosomal dominant polycystic liver disease.
Epac1 (Montrer RAPGEF3 Anticorps) is involved in AC5-mediated catecholamine stress-induced cardiac fibrosis. Epac1 (Montrer RAPGEF3 Anticorps) is involved in AC5-mediated elongation of atrial fibrillation.
In this study, we report that in the striatum AC5 exists in a stable pre-coupled complex with subunits of Golf heterotrimer.
changes in adipose tissue ADCY5 expression are related to obesity and fat distribution.
these results suggest that AnxA4 (Montrer ANXA4 Anticorps) is a novel direct negative regulator of AC5, adding a new facet to the functions of annexins.
These results identify the AC5 and mGluR system in the dorsal striatum as molecular on/off switches to direct decisions on behavioral preferences for cue-oriented options
deficiency of AC5 protects against obesity, glucose intolerance, and insulin (Montrer INS Anticorps) resistance.
Describe developmental expression of adenylyl cyclase 5.
our data suggest that AC5 is the prevalent adenylyl cyclase isoform in rabbit renal cortex
This gene encodes a member of the membrane-bound adenylyl cyclase enzymes. Adenylyl cyclases mediate G protein-coupled receptor signaling through the synthesis of the second messenger cAMP. Activity of the encoded protein is stimulated by the Gs alpha subunit of G protein-coupled receptors and is inhibited by protein kinase A, calcium and Gi alpha subunits. Single nucleotide polymorphisms in this gene may be associated with low birth weight and type 2 diabetes. Alternatively spliced transcript variants that encode different isoforms have been observed for this gene.
adenylate cyclase type 5
, adenylyl cyclase type V
, adenylate cyclase 5
, ATP pyrophosphate-lyase 5
, adenylate cyclase type V
, adenylyl cyclase 5
, ca(2+)-inhibitable adenylyl cyclase